Tanyi, J.L., Smith, J.A., Ramos, L., Parker, C.L., Munsell, M.F., & Wolf, J.K. (2009). Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecologic Oncology, 114, 219–224.
To evaluate the efficacy and safety profile of pegylated liposomal doxorubicin (PLD) (Doxil®) at different doses, as well as predictive factors of palmar-plantar erythrodysesthesia (PPE).
The regional cooling mechanism comprised application of ice packs to the wrists and ankles during PLD administration.
University of Texas MD Anderson Cancer Center in Houston
This was a retrospective chart review.
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE); version not specified
Higher doses and additional cycles of PLD were associated with a higher incidence of adverse reactions, including PPE. Potential predictors of PPE were use of cooling mechanisms, higher numbers of PLD cycles given, occurrence of mucositis, neutropenia, and peripheral neuropathy.
This was a retrospective study only.